Enanta Pharmaceuticals (ENTA) Leases (2019 - 2025)
Historic Leases for Enanta Pharmaceuticals (ENTA) over the last 7 years, with Q3 2025 value amounting to $37.5 million.
- Enanta Pharmaceuticals' Leases fell 764.67% to $37.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.5 million, marking a year-over-year decrease of 764.67%. This contributed to the annual value of $37.5 million for FY2025, which is 764.67% down from last year.
- Enanta Pharmaceuticals' Leases amounted to $37.5 million in Q3 2025, which was down 764.67% from $38.2 million recorded in Q2 2025.
- Over the past 5 years, Enanta Pharmaceuticals' Leases peaked at $41.2 million during Q2 2024, and registered a low of $4.7 million during Q3 2021.
- Its 5-year average for Leases is $25.6 million, with a median of $23.6 million in 2022.
- In the last 5 years, Enanta Pharmaceuticals' Leases crashed by 3289.17% in 2021 and then skyrocketed by 40042.45% in 2022.
- Over the past 5 years, Enanta Pharmaceuticals' Leases (Quarter) stood at $18.8 million in 2021, then rose by 24.99% to $23.5 million in 2022, then decreased by 9.33% to $21.3 million in 2023, then surged by 85.88% to $39.7 million in 2024, then decreased by 5.36% to $37.5 million in 2025.
- Its Leases stands at $37.5 million for Q3 2025, versus $38.2 million for Q2 2025 and $39.1 million for Q1 2025.